October 01, 2014 5:35 PM ET

Biotechnology

Company Overview of Celgene International Sarl

Company Overview

Celgene International Sarl operates as a biopharmaceutical company. It discovers, develops, and commercializes therapies to treat cancer and immune-inflammatory related diseases in the United States and internationally. The company was incorporated in 2003 and is based in Boudry, Switzerland. Celgene International Sarl operates as a subsidiary of Celgene Corporation.

Route de Perreux 1

Boudry,  2017

Switzerland

Founded in 2003

Phone:

41 32 729 85 00

Fax:

41 32 729 85 08

Key Executives for Celgene International Sarl

President of Europe
Compensation as of Fiscal Year 2014.

Celgene International Sarl Key Developments

Celgene International Sarl Announces Approval for ABRAXANE from Swissmedic

Celgene International Sarl announced that Swissmedic has granted approval for ABRAXANE (paclitaxel formulated as albumin bound nanoparticles, or nab-paclitaxel) as a treatment for metastatic pancreatic cancer (in combination with gemcitabine), and as a treatment for metastatic breast cancer.

Celgene International Sàrl Announces Executive Changes

Celgene International Sàrl announced that Tuomo Pätsi has been appointed President of the Europe, Middle East and Africa (EMEA) region for the company. In this role, he will oversee the current portfolio in EMEA as well as international efforts related to the company's broad pipeline of clinical programs in areas including immunotherapy, epigenetics, ubiquitin ligase targets, cancer metabolism and others. Mr. Pätsi takes over from Alan Colowick, MD, who has led Celgene in the region since 2012 and who returns to the United States, taking on another senior strategic position for the company. Mr. Pätsi's appointment as President follows more than 7 years with the company. Most previously, he served as Corporate Vice President for the South Europe Region; as General Manager, Regional Vice President for the North Europe Region; and as Head of European Marketing.

Celgene International Sarl Names Tuomo Patsi as President of its Europe, Middle East and Africa Region Replacing Alan Colowick

Celgene Corp.'s unit, Celgene International Sarl, announced that Tuomo Patsi has been named as president of the company's Europe, Middle East and Africa or EMEA region. He would oversee the present portfolio in EMEA and international efforts related to the firm's broad pipeline of clinical programs in areas like immunotherapy, epigenetics, ubiquitin ligase targets, cancer metabolism and others. Patsi takes over from Alan Colowick, MD, who has headed Celgene in the region since 2012 and who returns to the U.S., taking on another senior strategic position for the company. His appointment as president follows over 7 years with the company. Most recently, he served as Corporate Vice President for the South Europe Region; as General Manager, Regional Vice President for the North Europe Region; and as Head of European Marketing.

Similar Private Companies By Industry

Company Name Region
Vaximm AG Europe
Idiag AG Europe
BOWS Pharmaceuticals AG Europe
Glaxo Institute for Molecular Biology Europe
Molecular Partners AG Europe

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Celgene International Sarl, please visit www.celgene.eu. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.